Catalent Pharma Solutions has acquired the remaining stake in Redwood Bioscience Inc., along with the SMARTag Antibody-Drug Conjugate (ADC) technology platform. The acquisition is part of Catalent’s strategy to add differentiated technology and to strengthen its position in the biologics market.
 
The acquisition follows successful in vivo and in vitro proof of concept milestones providing compelling in vivo toxicology data and strong customer interest in the SMARTag technology. Redwood’s team in Emeryville, CA will become part of Catalent’s network, led by Redwood president, chief scientific officer and founder, David Rabuka.
 
In April 2013 Catalent acquired an exclusive license to market the SMARTag technology and has subsequently collaborated with Redwood for ongoing development and marketing of the platform.
 
“This acquisition brings to Catalent a highly differentiated technology in the SMARTag platform, as well as a high caliber and innovative scientific team,” commented John Chiminski, president and chief executive officer, Catalent Pharma Solutions. “It is aligned with our strategic focus on innovation and technology, and further demonstrates Catalent’s ability to strengthen our position in key growth markets through internal and external investments.”